Zaiqi Wang
9Patents
0h-index
11Co-inventors
34Inventor score
Filing activity: Jun 3, 2019 → Nov 6, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US12121519B2 | Use of BI853520 in cancer treatment | Human Necessities | 0 | Active |
| US11986477B2 | Drug combination and use for treating tumors | Human Necessities | 0 | Active |
| US12115160B2 | Combined use of IN10018 and PLD | Human Necessities | 0 | Active |
| US12064431B2 | Use of BI853520 in cancer treatment | General | 0 | Revoked |
| US11999719B2 | Solid form of compound | Chemistry; Metallurgy | 0 | Active |
| US12059421B2 | Use of BI853520 in cancer treatment | Human Necessities | 0 | Active |
| US12097200B2 | Combination of BI853520 with chemotherapeutic drugs | Chemistry; Metallurgy | 0 | Active |
| US11440916B2 | Selective A2A receptor antagonist | Human Necessities | 0 | Active |
| US12257251B2 | Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.